Excellent analysis of the REDUCE-IT study by @matthewherper, but there's one issue that I would like to point out as well https://www.forbes.com/sites/matthewherper/2018/11/10/fish-oil-derived-drug-shows-great-promise--with-big-caveats/#35596a333291 …
True, but the participants were already taking statins from my understanding? So the ICER would be compared to other cardiac medications, which may prevent more events or have a similar NNT but for a shorter time-period, all on top of statins
-
-
Sorry, when I say VERY expensive what I mean is the price per prevented event is high, not that the absolute cost is high
-
Willingness-to-pay is usually set at GDP, so a cost of $315,000 would be about 3x the WTP threshold in the US. If it's preventing deaths, that might come out cost-effective, but my guess is you'd have to halve the cost of the medication to see a positive CEA
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.